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Background
Corticosteroid and second line agents such as methotrex-
ate have dramatically improved the outcome for patients
with Juvenile Dermatomyositis (JDM). Nevertheless,
some patients suffer persisting disease activity despite
these treatments. Tacrolimus, an inhibitor of T-cell activa-
tion and proliferation, is one of the new therapeutic
options for JDM. However, little is known about its effi-
cacy in this patient group. We report the clinical course of
three patients with refractory JDM who were treated with
tacrolimus.
Patients
Three corticosteroid dependent children with extensive
skin disease and severe muscle weakness were started on
oral tacrolimus treatment and followed-up for 7–9
months. Patient 1: 11 year old boy, age of onset 6.1 years.
Patient 2: 7 year old girl, age of onset 5.8 years. Patient 3:
9 year old girl, age of onset 4.4 years.
Results
All three patients showed impressive improvement of
mainly the cutaneous lesions, and overall disease activity
decreased along with the muscle enzyme levels (Figure 1),
while corticosteroids could be tapered. All children
became more physically active. None of the patients
showed recovery of muscle strength, probably due to irre-
versible muscle damage related to the long-standing
myositis.
Conclusion
Tacrolimus is an effective and safe second line agent in the
treatment of chronic refractory JDM and improves the
skin involvement substantially.
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Course of muscle enzyme levels after the start of tacrolimus in patient 1, representative also for the other patients Figure 1
Course of muscle enzyme levels after the start of tacrolimus in patient 1, representative also for the other patients. Reference 
ranges: ASAT 0–30 U/L, LD 0–325 U/L, CK 0–145 U/L.